Detalhe da pesquisa
1.
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
Future Oncol
; 10(2): 219-31, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24490608
2.
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.
Lancet Oncol
; 13(11): 1114-24, 2012 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-23059046
3.
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
J Clin Endocrinol Metab
; 97(2): 507-16, 2012 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-22170708
4.
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
J Clin Oncol
; 28(9): 1489-95, 2010 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-20159823
5.
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
J Clin Oncol
; 27(23): 3742-8, 2009 Aug 10.
Artigo
Inglês
| MEDLINE | ID: mdl-19470933
6.
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Cancer Res
; 69(7): 2912-8, 2009 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-19339269